---
title: "GRAL: Q2 2026 delivered strong revenue growth and clinical milestones, with FDA approval anticipated in 2027"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295025166.md"
description: "Q2 2026 saw strong revenue and test volume growth, driven by Galleri's robust clinical validation and expanded commercial efforts. The company completed a $110M investment from Samsung, advanced toward FDA approval, and continued international expansion, while maintaining a strong cash position.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-05T22:30:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295025166.md)
  - [en](https://longbridge.com/en/news/295025166.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295025166.md)
generator: "portal-rs"
---

# GRAL: Q2 2026 delivered strong revenue growth and clinical milestones, with FDA approval anticipated in 2027

Q2 2026 saw strong revenue and test volume growth, driven by Galleri's robust clinical validation and expanded commercial efforts. The company completed a $110M investment from Samsung, advanced toward FDA approval, and continued international expansion, while maintaining a strong cash position.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [GRAL.US](https://longbridge.com/en/quote/GRAL.US.md)
- [SSNGY.US](https://longbridge.com/en/quote/SSNGY.US.md)
- [SMSN.UK](https://longbridge.com/en/quote/SMSN.UK.md)

## Related News & Research

- [Grail CEO Joshua J. Ofman sells 5,000 common shares for $425,098](https://longbridge.com/en/news/297572646.md)
- [Grail grants 55,867 inducement RSUs to 59 new hires under Nasdaq rule 5635(c)(4)](https://longbridge.com/en/news/297952292.md)
- [AI Was Supposed to Kill Wix. Google Just Gave It a Way to Fight Back.](https://longbridge.com/en/news/297433684.md)
- [Insider Selling: GRAIL (NASDAQ:GRAL) CFO Sells $671,579.00 in Stock](https://longbridge.com/en/news/297577183.md)
- [CRET: Q2 2026 saw higher sales and improved margins, but growth is limited by financing constraints](https://longbridge.com/en/news/297468890.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**